10 February 2019

Circular No. 16 Adding warnings to the pharmaceutical product Lemtrade (Alemtuzumab)

Reference: CIR-2019-00000045

circular # 16 - Adding warnings to the pharmaceutical product Lemtrade (Alemtuzumab)

To all health facilities / all health care practitioners in Dubai's private health sector

 

please refer to the circular # 16 regarding the  Adding warnings to the pharmaceutical product  Lemtrade (Alemtuzumab)

 

Supporting Documents:

circular 16.pdf:

View Document